This Week in CRC Research

TRIAL DATA

Aflibercept plus 5-FU shows promise for frail elderly patients with metastatic colorectal cancer — European Journal of Cancer

The phase II ELDERLY trial compared two first-line treatment options for older adults (age 70+) or frail patients with metastatic colorectal cancer who aren't eligible for full-dose chemotherapy combinations. Patients received either dose-reduced mFOLFOX7 (a chemotherapy doublet with oxaliplatin and fluorouracil) or aflibercept (an angiogenesis inhibitor that blocks blood vessel formation in tumors) combined with 5-FU. This non-comparative study evaluated whether these gentler regimens could provide benefit while minimizing toxicity in a vulnerable patient population.

What this means

If you're over 70 or have other health conditions that make standard chemotherapy too harsh, this trial provides evidence for treatment options specifically designed for your situation. Discuss with your oncologist whether a dose-reduced regimen might be appropriate for your care.

TRIAL DATA

Neoadjuvant chemotherapy alone may be as effective as chemoradiation for some rectal cancers — Journal of Clinical Oncology

The phase III CONVERT trial compared neoadjuvant chemotherapy (CAPOX — capecitabine plus oxaliplatin) with traditional chemoradiation for locally advanced rectal cancer patients whose tumors haven't invaded the mesorectal fascia (the tissue layer surrounding the rectum). Final results show that chemotherapy alone may spare patients from radiation side effects while achieving similar outcomes. This challenges the standard practice of always using radiation before surgery for locally advanced rectal cancer.

What this means

If you have rectal cancer that hasn't spread to the mesorectal fascia, you may be able to avoid radiation therapy and its long-term side effects (such as bowel dysfunction and sexual problems) while still receiving effective treatment. Ask your care team whether chemotherapy alone might be an option for your specific tumor.

SCREENING

Blood-based circulating tumor DNA shows promise for early colorectal cancer detection — Digestive Diseases

A systematic review and meta-analysis evaluated the accuracy of blood-based circulating tumor DNA (ctDNA) tests for detecting colorectal cancer in people without symptoms. These tests look for tiny fragments of tumor DNA that circulate in the bloodstream. The analysis included prospective and cross-sectional studies comparing ctDNA assays (which detect mutations, methylation patterns, or DNA fragments) against standard diagnostic methods. Results suggest these non-invasive blood tests could complement existing screening approaches.

What this means

Blood-based screening tests may eventually offer a convenient alternative to stool tests or colonoscopy, though they're not yet widely available or FDA-approved for routine screening. If you're avoiding colonoscopy, talk to your doctor about currently approved screening options while these blood tests continue development.

TRIAL DATA

Circulating tumor DNA testing after surgery predicts recurrence in stage III colon cancer — Journal of Clinical Oncology

Analysis from the phase III Alliance N0147 trial evaluated a tissue-free circulating tumor DNA (ctDNA) assay in patients receiving FOLFOX-based adjuvant chemotherapy after surgery for stage III colon cancer. The study examined whether detecting ctDNA in blood samples after surgery could predict which patients would experience cancer recurrence. This "liquid biopsy" approach doesn't require analyzing the original tumor tissue, making it more accessible for monitoring patients after treatment.

What this means

If you've had surgery for stage III colon cancer, ctDNA testing may help your care team identify whether you're at higher risk for recurrence and need closer monitoring or different treatment strategies. Ask your oncologist whether ctDNA testing is available and appropriate for your follow-up care.

TRIAL DATA

Real-world study identifies factors predicting immunotherapy response in MSI-H/dMMR gastrointestinal cancers — ESMO Real World Data and Digital Oncology

A multicenter retrospective study of 122 patients with advanced MSI-H/dMMR (microsatellite instability-high/mismatch repair deficiency) gastrointestinal tumors treated with immune checkpoint inhibitors across eight Spanish university hospitals examined which clinical factors predict treatment outcomes. MSI-H/dMMR tumors have defects in DNA repair that make them particularly responsive to immunotherapy. The study included both colorectal cancer and non-colorectal GI cancers to understand response patterns across different tumor types.

What this means

If your tumor is MSI-H or dMMR, immunotherapy is likely to be part of your treatment plan. This real-world evidence helps doctors understand which patients benefit most. Make sure your tumor has been tested for MSI/MMR status — if it hasn't, ask your oncologist about testing.

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Study identifies prognostic factors for young adults with liver metastases — Discover Oncology

Researchers analyzed 3,188 young adults (ages 18-45) with stage IV colorectal cancer and liver metastases from the SEER database to identify factors associated with overall survival. The study aims to help clinicians better predict outcomes and tailor treatment for younger patients, who often present with more aggressive disease.

Three decades of data reveal changing patterns in early-onset colorectal cancer — Journal of Surgical Oncology

A multicentre study from Sweden and Finland examined how demographic and clinical features of early-onset colorectal cancer (diagnosed before age 50) have changed between 1995 and 2020. Understanding these trends helps researchers identify risk factors and improve early detection strategies for younger populations.

Commentary examines whether early-onset CRC represents new risk factors or earlier exposure — Cancer Epidemiology, Biomarkers & Prevention

An expert commentary discusses the rising rates of colorectal cancer in people under 50, particularly those under 45 where screening isn't yet standard. The piece questions whether we're seeing entirely new risk factors or whether known risk factors are affecting people at younger ages.

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

KRAS G12C inhibitor plus cetuximab shows activity in first-line lung cancer — The Lancet Oncology

The phase 1b/2 KROCUS trial tested fulzerasib (a KRAS G12C inhibitor) combined with cetuximab (an EGFR antibody) in previously untreated non-small-cell lung cancer patients with KRAS G12C mutations. While this study focused on lung cancer, the combination strategy has shown promise in colorectal cancer and may inform future CRC trials.

Case report: Re-challenging BRAF V600E mutated CRC with encorafenib, cetuximab, and nivolumab — Clinical Colorectal Cancer

A case report from the AGMT mCRC Registry describes successful re-treatment with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch repair-proficient metastatic colorectal cancer. This suggests that re-challenging with targeted therapy plus immunotherapy may be feasible in select patients.

New compounds show selective activity against KRAS-mutated colorectal cancer cells — Anticancer Drugs

Researchers identified 3-aminoisoquinolines as potential selective inhibitors of phosphodiesterase 4B (PDE4B), which is overexpressed in KRAS-mutated colorectal cancer. Laboratory studies showed these compounds inhibit cancer cell growth both in cell cultures and in animal models, suggesting a new therapeutic approach for KRAS-mutated tumors.

Low expression of DNA repair genes may predict benefit from chemotherapy — JCO Precision Oncology

Analysis of 22,957 metastatic CRC samples investigated whether low RNA expression of homologous recombination (HR) genes identifies patients who benefit from oxaliplatin- or irinotecan-based chemotherapy. The study refines our understanding of DNA repair deficiency beyond traditional genomic markers.

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Fecal hemoglobin levels can guide precision surveillance after polyp removal — Gastroenterology

A study of four million participants in FIT-based screening programs developed fecal hemoglobin-guided surveillance intervals after polyp removal. The research shows that measuring fecal hemoglobin concentration can help determine optimal timing for follow-up colonoscopy, potentially reducing unnecessary procedures while maintaining cancer prevention.

Network analysis identifies most effective interventions to increase screening uptake — Gastroenterology

A systematic review and network meta-analysis of 76 randomized clinical trials evaluated eight different strategies to improve colorectal cancer screening rates, including patient navigation, reminders, and educational interventions. The study helps identify which approaches work best to get more people screened.

Review examines population screening programs across Asia — Journal of Gastroenterology and Hepatology

A comprehensive analysis of established national colorectal cancer screening programs in Japan, South Korea, and Taiwan compares strategies, effectiveness, and quality assurance frameworks. Asia is now the global epicenter of colorectal cancer, making these programs critical for disease control.

⚥ Sex & Gender in CRC

Research on sex-specific differences in treatment, outcomes, and screening

Major analysis reveals sex differences in treatment efficacy and toxicity — European Journal of Cancer

Analysis of 18,041 patients in the ARCAD CRC database examined sex differences in efficacy and toxicity of first-line treatment for metastatic colorectal cancer. This large-scale study helps identify whether men and women respond differently to standard chemotherapy regimens and experience different side effects.

Clinical Trials Update

Phase II trial tests pembrolizumab plus capecitabine and bevacizumab in MSS/pMMR metastatic CRC — Clinical Colorectal Cancer

A phase II study evaluated pembrolizumab (an immune checkpoint inhibitor) combined with capecitabine and bevacizumab in microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. MSS/pMMR tumors typically don't respond well to immunotherapy alone, so this combination approach aims to overcome resistance by adding chemotherapy and anti-angiogenesis therapy.

AZUR-4 trial launches: Testing dostarlimab plus chemotherapy before surgery — Clinical Colorectal Cancer

The phase II AZUR-4 trial is recruiting patients with T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer. The study compares neoadjuvant dostarlimab (an immune checkpoint inhibitor) plus CAPEOX chemotherapy versus CAPEOX alone before surgery. This tests whether adding immunotherapy before surgery improves outcomes even in tumors that typically don't respond well to immunotherapy.

FIERCE study assesses safety of trifluridine/tipiracil with radiation in rectal cancer — Clinical Colorectal Cancer

The phase Ib FIERCE study evaluates the safety of neoadjuvant trifluridine/tipiracil (an oral chemotherapy) with concurrent radiation in resectable stage II/III rectal cancer. Phase Ib trials test safety and determine the right dose before moving to larger efficacy studies.

Long-term results: Adjuvant chemotherapy after liver metastasis surgery — Journal of Clinical Oncology

The randomized phase II/III JCOG0603 trial compared hepatectomy (liver surgery) followed by mFOLFOX6 chemotherapy versus hepatectomy alone for liver metastases from colorectal cancer. Long-term results help determine whether chemotherapy after surgery for liver metastases improves survival.

By the Numbers

122 patients

The number of patients with advanced MSI-H/dMMR gastrointestinal tumors analyzed in a multicenter real-world study of immune checkpoint inhibitor therapy across eight Spanish hospitals. Real-world evidence like this complements clinical trial data by showing how treatments perform in everyday practice, including patients who might not qualify for trials due to age, other health conditions, or prior treatments. Source: ESMO Real World Data and Digital Oncology

Resources

Understanding Biomarker Testing

The CRC Digest

Research intelligence for the colorectal cancer community

Get CRC research intelligence delivered weekly — free.

Subscribe

Not Medical Advice

The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.

Content is curated with AI assistance and reviewed by the editorial team.

Browse Past Issues

Read our full disclaimer

Manage subscription